Service
In vitro and in vivo models with high risk pathogens
Our Bsl2 and Bsl3 facilities allow to perform in vitro and in vivo studies with high risk pathogens.
Marketing Team Leader at TAKIS SRL
rome, Italy
Takis is a biotechnology company specializing in the research and development of innovative immunotherapies for infectious diseases and oncology. Its expertise includes DNA vaccines and humanized monoclonal antibodies. The company is equipped with BSL3 facilities for research on high-risk pathogens and GMP laboratories for the production of clinical-grade nucleic acids. Takis developed COVID-eVax, a DNA-based COVID-19 vaccine demonstrated to be safe and immunogenic in a first-in-human Phase 1 trial.
Takis provides fee-for-service solutions, including preclinical in vitro and in vivo studies, monoclonal antibody generation, vaccine development, and customized immune-oncology research services.
Marketing Team Leader
TAKIS SRL
Chief Technology Officer
TAKIS SRL
Service
In vitro and in vivo models with high risk pathogens
Our Bsl2 and Bsl3 facilities allow to perform in vitro and in vivo studies with high risk pathogens.
Marketing Team Leader at TAKIS SRL
rome, Italy
Marketing Team Leader at TAKIS SRL
rome, Italy
Service
Recombinant antibodies ensure a safe long-term supply, with minimal batch-to-batch variation.
Marketing Team Leader at TAKIS SRL
rome, Italy
Service
Next-generation vaccines development
We can generate innovative genetic vaccines able to induce a strong immune response while minimizing potential undesired effects.
Marketing Team Leader at TAKIS SRL
rome, Italy